Home Search
immunotherapy - search results
If you're not happy with the results, please do another search
Study Shows miRNA Can Predict NSCLC Patient Survival After Immunotherapy
The results point to miRisk being able to determine whether patients with advanced-stage NSCLC should receive only immunotherapy (IO) or if they should receive immunotherapy in combination with chemotherapy (ICT).
Diverse CAR Libraries Could Aid Cancer Immunotherapy Development
New research reports the development and applicability of libraries of immune cells displaying diverse repertoires of CARs that can recognize non-self antigens and display antigen-dependent clonal expansion.
MD Anderson: Ultrasound-Guided Microbubbles Improved Immunotherapy
The approach employs nanocomplexes combined with microbubbles to deliver cyclic guanosine monophosphate-adenosine monophosphate into antigen-presenting cells.
Novel Method May Predict HCC Immunotherapy Response
Researchers at Osaka University report they have developed an analytical method that could help predict if an HCC patient would successfully respond to immunotherapy.
Immunotherapy Reduces Bladder Cancer Recurrence
Results from the CheckMate 274 trial show that adjuvant immunotherapy with nivolumab after surgery and chemotherapy helped reduce bladder cancer recurrence in patients with urothelial cancer of the bladder.
T-Cell Behavior in Tumors Affects Immunotherapy Response
The study indicates that the genetic program of T lymphocyte immune cells infiltrating malignant tumors, and the developmental path that these T cells then follow, may affect their response to immunotherapy.
Failed Trial Provides Insights to Preventing Immunotherapy Adverse Events
Some people see no change after immunotherapy, but others develop serious problems in their lungs, bowel, and even skin during treatment. These side effects can be debilitating and even fatal.
Researchers Find a New Target for Cancer Immunotherapy
Researchers observed the differences in intratumoral immune responses between male and female cancers of non-reproductive origin.
Data Hints at Omega-3 Role in Boosting Immunotherapy
The research also revealed that consumption of high levels of omega-6 fatty acids—common in American diets—was associated with a poor response to immunotherapy
New Advanced Melanoma Immunotherapy Regimen Approved by FDA
The FDA has approved the use of the anti-lymphocyte-activation gene (LAG)-3 agent relatlimab in combination with the anti-programmed death (PD)-1 drug nivolumab for patients with treatment-naïve advanced melanoma.
